Leveraging Knowledge From Cytotoxic ADCs & Other Modalities to Assess Pharmacology Profiles of Next- Generation ADCs

  • Leveraging systems pharmacology modeling to understand ADC behavior and MoA
  • Combining knowledge from novel payloads with classical cytotoxic ADCs to impact future ADC constructs
  • Utilizing pharmacology characterization to assist with translation and first-in-human dosing strategy